Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation
- PMID: 17238026
- DOI: 10.1007/s00535-006-1942-7
Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation
Abstract
Corticotropin-releasing hormone (CRH) is a major mediator of stress response in the brain-gut axis. Irritable bowel syndrome (IBS) is presumed to be a disorder of the brain-gut link associated with exaggerated response to stress. We first showed that peripheral administration of CRH aggravated visceral sensorimotor function as well as adrenocorticotropic hormone (ACTH) response in IBS patients. We then administered alpha-helical CRH (alphahCRH), a non-selective CRH receptor antagonist among IBS patients. Electrical stimulation of the rectum induced significantly higher motility indices of the colon in IBS patients than in the controls. This response was significantly suppressed in IBS patients but not in the controls after administration of alphahCRH. Administration of alphahCRH induced a significant increase in the barostat bag volume of the controls but not in that of IBS patients. alphahCRH significantly reduced the ordinate scale of abdominal pain and anxiety evoked by electrical stimulation in IBS patients. Plasma ACTH and serum cortisol were generally not suppressed by alphahCRH. Last, administration of CRH1-receptor (CRH-R1) specific antagonist blocked colorectal distention-induced sensitization of the visceral perception in rats. Moreover, pretreatment with CRH-R1 antagonist blocked colorectal distention-induced anxiety, which was measured with elevated plus-maze, in rats. Evidence supporting the concept that peripheral CRH and CRH-R1 play important roles in brain-gut sensitization is increasing. Several studies have identified immunoreactive CRH and urocortin as well as CRH-R1 and CRH-R2 mRNAs in human colonic mucosa. In addition, reverse transcription-polymerase chain reaction has revealed the expression of CRH-R1 mRNA in both the myenteric and submucosal plexus in the guinea pig. Application of CRH has been shown to evoke depolarizing responses associated with elevated excitability in both myenteric and submucosal neurons. On the other hand, peripheral injection of CRH has been reported to induce discrete effects on colonic secretory and motor function, and permeability. There are functional differences between CRH-R1 and CRH-R2. For instance, activation of CRH-R1 causes a proinflammatory response, whereas stimulation of CRH-R2 provokes anti-inflammatory changes. In addition, there is evidence of the contrasting roles of CRH-R1 and CRH-R2 in visceral nociception. While CRH-R1 is involved in the pro-nociceptive effects of visceral pain, CRH-R2 mediates an anti-nociceptive response. These findings suggest the major role of CRH in stress-related pathophysiology of IBS and possibly in inflammation of the intestinal mucosa.
Similar articles
-
Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome.Gut. 2004 Jul;53(7):958-64. doi: 10.1136/gut.2003.018911. Gut. 2004. PMID: 15194643 Free PMC article.
-
Differential Activation in Amygdala and Plasma Noradrenaline during Colorectal Distention by Administration of Corticotropin-Releasing Hormone between Healthy Individuals and Patients with Irritable Bowel Syndrome.PLoS One. 2016 Jul 22;11(7):e0157347. doi: 10.1371/journal.pone.0157347. eCollection 2016. PLoS One. 2016. PMID: 27448273 Free PMC article.
-
Visceral hypersensitivity in irritable bowel syndrome.J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:119-21. doi: 10.1111/j.1440-1746.2011.06640.x. J Gastroenterol Hepatol. 2011. PMID: 21443723
-
Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome.Gastroenterology. 2013 Dec;145(6):1253-61.e1-3. doi: 10.1053/j.gastro.2013.08.016. Epub 2013 Aug 14. Gastroenterology. 2013. PMID: 23954313 Free PMC article. Review.
-
Stress and visceral pain: focusing on irritable bowel syndrome.Pain. 2013 Dec;154 Suppl 1:S63-S70. doi: 10.1016/j.pain.2013.09.008. Epub 2013 Sep 8. Pain. 2013. PMID: 24021863 Review.
Cited by
-
The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome.J Clin Med. 2024 Aug 29;13(17):5124. doi: 10.3390/jcm13175124. J Clin Med. 2024. PMID: 39274340 Free PMC article. Review.
-
Pharmacogenetics in IBS: update and impact of GWAS studies in drug targets and metabolism.Expert Opin Drug Metab Toxicol. 2024 May;20(5):319-332. doi: 10.1080/17425255.2024.2349716. Epub 2024 May 26. Expert Opin Drug Metab Toxicol. 2024. PMID: 38785066 Review.
-
Role of CRH in colitis and colitis-associated cancer: a combinative result of central and peripheral effects?Front Endocrinol (Lausanne). 2024 Mar 28;15:1363748. doi: 10.3389/fendo.2024.1363748. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38616821 Free PMC article. Review.
-
The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome-Plant Metabolites in IBS Treatment.Pharmaceuticals (Basel). 2023 Oct 3;16(10):1405. doi: 10.3390/ph16101405. Pharmaceuticals (Basel). 2023. PMID: 37895876 Free PMC article. Review.
-
Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review.World J Clin Cases. 2023 Jul 6;11(19):4458-4476. doi: 10.12998/wjcc.v11.i19.4458. World J Clin Cases. 2023. PMID: 37469740 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
